FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310108032> ?p ?o ?g. }

• W4310108032 endingPage "9940" @default.
• W4310108032 startingPage "9939" @default.
• W4310108032 abstract "Multiple myeloma (MM) is a malignancy of clonal plasma cells with identical variable-diversity-joining (VDJ) region recombination of immunoglobulin loci (called repertoire) and extensive genome or transcriptome heterogeneity. Even though many new treatment modalities have been developed and the prognosis of patients has improved significantly, most cases of MM remain incurable. Recent evidence suggests that non-genetic cell plasticity and changes in cell state underlie the therapy resistance and tumor relapse, but the mechanisms remain largely unknown. Here, we have attempted to understand comprehensive architecture of the entire tumor cell populations using repertoire clonality as fingerprint. First, we subdivided bone marrow samples of primary MM at different stages (n=8) into 11 fractions based on the known surface antigens of MM and performed bulk RNA sequencing (bulk RNA-seq). Analysis of the repertoire revealed that tumor cells were also present in some minor fractions other than the main fraction (Lin-/CD19-/CD38++/CD138+) as the stage progressed. Importantly, cells with clonal repertoire were detected in CD138 negative fraction (Lin-/CD19-/CD38++/CD138-) in most samples (Monoclonal gammopathy of undetermined significance (MGUS) / Smoldering multiple myeloma (SMM) = 4.15±2.28%, Primary MM = 6.78±3.59%, Relapse MM = 7.8±5.82% [mean±95%Cl], n=24). The CD138 positive and negative cells were also morphologically different, suggesting that they were composed by cells of distinct characteristics. Indeed, comparison of the transcriptome data revealed 296 differentially expressed genes (DEGs) between these fractions (250 up-regulated and 46 down-regulated in CD138 negative fractions). Of interest, several pathways related to H3K4 methylation were positively enriched in CD138 negative fraction (p <0.001), which included KMT2A, KMT2B, KMT2C, KMT2D, and ASH1L, suggesting that differential methylation of histone H4 accounts for the heterogeneity of MM. In order to achieve a high-resolution and comprehensive evaluation of the entire tumor cell populations, we performed single-cell RNA sequencing (scRNA-seq) and single-cell VDJ targeted sequencing (scVDJ-seq) concurrently on Lin-/CD38++ sorted cells of 8 bone marrow samples from 7 patients including pre- and post-treatment status samples. This method allowed us to define normal cells and MM cells at the single-cell level by clonal repertoire sequence independent of transcriptome characteristics. We divided 18,031 MM cells into 23 clusters after integration. We first defined CD138 positive and negative MM gene signature using bulk RNA-seq data and then evaluated the scRNA-seq data. Notably, the CD138 axis appeared to clearly subdivide main MM populations into those with CD138 positive and negative MM gene signature. We also found that a part of clusters, which showed CD138 negative MM gene signature, tended to remain at high proportions after treatment. These populations were characterized by low expression levels of MHC class-I components and TNFRSF17/BCMA as well as high expression of MCL1, MALAT1 and NEAT1, which have been previously implicated in treatment resistance, and were present in all samples. H3K4 methylation related genes were also up-regulated in these populations. Furthermore, we found several clusters with unique and interesting characteristics independent of the CD138 axis. Trajectory and velocity analysis suggested that all cell populations transit to each other. Taken together, our results establish the heterogeneity of MM cells by the CD138 axis, which may be characterized by epigenetic plasticity. They also highlight CD138 negative population as a potential cause of treatment resistance and relapse. By using information of repertoire, we have achieved a comprehensive and accurate single-cell analysis of MM cell diversity that was not limited by cell surface antigens or transcriptome characteristics. We are currently analyzing near minimal residual disease (MRD) level samples using the same scRNA-seq methods and the functional and epigenetic properties of CD138 positive and negative MM cells." @default.
• W4310108032 created "2022-11-30" @default.
• W4310108032 creator A5010952206 @default.
• W4310108032 creator A5018418725 @default.
• W4310108032 creator A5029593209 @default.
• W4310108032 creator A5045575841 @default.
• W4310108032 creator A5061355885 @default.
• W4310108032 creator A5070130441 @default.
• W4310108032 creator A5071242905 @default.
• W4310108032 creator A5079282630 @default.
• W4310108032 creator A5080164101 @default.
• W4310108032 creator A5086949282 @default.
• W4310108032 date "2022-11-15" @default.
• W4310108032 modified "2023-10-01" @default.
• W4310108032 title "Unraveling the Heterogeneity of Multiple Myeloma Cells By Single-Cell RNA Sequencing Analysis" @default.
• W4310108032 doi "https://doi.org/10.1182/blood-2022-166085" @default.
• W4310108032 hasPublicationYear "2022" @default.
• W4310108032 type Work @default.
• W4310108032 citedByCount "0" @default.
• W4310108032 crossrefType "journal-article" @default.
• W4310108032 hasAuthorship W4310108032A5010952206 @default.
• W4310108032 hasAuthorship W4310108032A5018418725 @default.
• W4310108032 hasAuthorship W4310108032A5029593209 @default.
• W4310108032 hasAuthorship W4310108032A5045575841 @default.
• W4310108032 hasAuthorship W4310108032A5061355885 @default.
• W4310108032 hasAuthorship W4310108032A5070130441 @default.
• W4310108032 hasAuthorship W4310108032A5071242905 @default.
• W4310108032 hasAuthorship W4310108032A5079282630 @default.
• W4310108032 hasAuthorship W4310108032A5080164101 @default.
• W4310108032 hasAuthorship W4310108032A5086949282 @default.
• W4310108032 hasBestOaLocation W43101080321 @default.
• W4310108032 hasConcept C104317684 @default.
• W4310108032 hasConcept C1491633281 @default.
• W4310108032 hasConcept C203014093 @default.
• W4310108032 hasConcept C2776364478 @default.
• W4310108032 hasConcept C2776950831 @default.
• W4310108032 hasConcept C54355233 @default.
• W4310108032 hasConcept C67705224 @default.
• W4310108032 hasConcept C70721500 @default.
• W4310108032 hasConcept C86803240 @default.
• W4310108032 hasConceptScore W4310108032C104317684 @default.
• W4310108032 hasConceptScore W4310108032C1491633281 @default.
• W4310108032 hasConceptScore W4310108032C203014093 @default.
• W4310108032 hasConceptScore W4310108032C2776364478 @default.
• W4310108032 hasConceptScore W4310108032C2776950831 @default.
• W4310108032 hasConceptScore W4310108032C54355233 @default.
• W4310108032 hasConceptScore W4310108032C67705224 @default.
• W4310108032 hasConceptScore W4310108032C70721500 @default.
• W4310108032 hasConceptScore W4310108032C86803240 @default.
• W4310108032 hasIssue "Supplement 1" @default.
• W4310108032 hasLocation W43101080321 @default.
• W4310108032 hasOpenAccess W4310108032 @default.
• W4310108032 hasPrimaryLocation W43101080321 @default.
• W4310108032 hasRelatedWork W1828691184 @default.
• W4310108032 hasRelatedWork W1903732681 @default.
• W4310108032 hasRelatedWork W1991523530 @default.
• W4310108032 hasRelatedWork W2002128513 @default.
• W4310108032 hasRelatedWork W2020824267 @default.
• W4310108032 hasRelatedWork W2031436818 @default.
• W4310108032 hasRelatedWork W2057739827 @default.
• W4310108032 hasRelatedWork W2075354549 @default.
• W4310108032 hasRelatedWork W2119103177 @default.
• W4310108032 hasRelatedWork W2092874662 @default.
• W4310108032 hasVolume "140" @default.
• W4310108032 isParatext "false" @default.
• W4310108032 isRetracted "false" @default.
• W4310108032 workType "article" @default.